A neonatal mouse model to study retrovirus-specific humoral responses
研究逆转录病毒特异性体液反应的新生小鼠模型
基本信息
- 批准号:10241945
- 负责人:
- 金额:$ 46.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAgeAllelesAnimalsAntibodiesAntibody ResponseAntigen PresentationBacterial Artificial ChromosomesBioinformaticsBirthBreast FeedingCandidate Disease GeneCellsChromosome 15Chromosome 17CodeDNA MarkersEvolutionExposure toGenesGeneticGoalsHIVHaplotypesHepatitis BHepatitis C virusHomologous GeneHumanI/LnJ MouseImmune responseImmune systemImmunityImpairmentInbred C57BL MiceInbred MouseInfectionInfection ControlKnock-outLinkMHC Class II GenesMajor Histocompatibility ComplexMapsMediatingMolecularMothersMouse Mammary Tumor VirusMurine leukemia virusMusMutateNamesNatural ResistanceNeonatalNewborn InfantPathway interactionsPenetrancePeptidesPhenotypePredispositionProductionResistanceResolutionRetroviridaeRoleSpleenTransgenic MiceVaccinesVirusgain of functiongene functiongenome wide association studygenomic locushuman diseaseinfection riskmouse modelneonatal miceneonateneutralizing antibodypathogenpositional cloningresistance generesponsetraitvirus identification
项目摘要
Project Summary
Only rare humans are naturally resistant to retroviral infections. Although genome wide association
studies can identify genetic loci associated with the resistance, finding particular resistance genes within gene-
rich loci has proven to be a great challenge. On the other hand, inbred mice offer a great alternative for
mapping mammalian genes responsible for resistance and susceptibility to retroviruses. We have described a
recessive locus named ‘virus infectivity controller 1’ (vic1), which is responsible for production of retrovirus-
neutralizing antibodies (Ab) in mice from the I/LnJ strain (2). vic1 mediates a neutralizing Ab response against
two different murine retroviruses (6, 2, 8). Thus, vic1 represents a mechanism of broad resistance against
retroviruses. Using positional cloning and computational approaches we identified H2-Ob (Ob) as the gene
coding for Vic1 (1). Ob encodes the beta subunit which together with alpha subunit, encoded by Oa, forms
evolutionally conserved the non-classical Major Histocompatibility Complex class II-like molecule H2-O (HLA-
DO in humans), a negative regulator of antigen presentation. The precise function of H2-O/HLA-DO is still
debated, but it appears to be related to its ability to modify the MHC-II peptide repertoire by inhibiting another
MHC-II-like molecule, H-2M (HLA-DM in humans) (9).
The role of non-functional Ob in retroviral resistance was confirmed by moving the I/LnJ allele of Ob to
several virus-susceptible backgrounds, such as C3H/HeN, B6, and BALB/cJ, and by producing a knock-out
allele of the gene in B6 mice. All these animals produced retrovirus-neutralizing Abs. However, the effect only
had high penetrance if these animals were infected as adults. In contrast, I/LnJ mice produced retrovirus-
neutralizing Abs irrespective of their age at infection, even when they were infected as newborns. The finding
prompted us to search for the genetic basis of resistance of I/LnJ neonates. The trait was successfully linked
to a single dominant 4.1 Mb region of Chromosome 15, virus infectivity controller 2 (vic2). Vic2 function was
only apparent in the absence of functional Ob. The inheritance of both non-functional Ob and vic2i conferred
the ability to produce anti-virus Abs to neonatal mice from all susceptible strains.
Many viruses, including retroviruses, infect adults, but are also passed from mothers to newborns
during birth and breastfeeding. It is commonly accepted that the immune system of a newborn is
underdeveloped, increasing the risk of infection and impairing responses to many vaccines. However, I/LnJ
mice generate a virus-neutralizing immune response independent of the age at which they were exposed to
the pathogen. Thus, it is fundamentally important to unravel the mechanism of Vic2’s function in order to
understand the unknown features of the neonate immune system and to acquire the ability of stimulating
productive pathogen-specific immunity in neonates. Identification of vic2 and the delineation of the pathway
that it controls are the goals of this proposal.
项目摘要
只有罕见的人天然对逆转录病毒感染具有抗性。虽然基因组范围的关联
研究可以鉴定与抗性相关的遗传局部,发现基因内的特定抗性基因
Rich Loci已被证明是一个巨大的挑战。另一方面,近交小鼠为
绘制负责抗逆转录病毒抗性和易感性的哺乳动物基因。我们已经描述了一个
隐性基因座为“病毒感染控制器1”(VIC1),该基因座负责产生逆转录病毒 -
来自I/LNJ菌株的小鼠中和抗体(AB)(2)。 VIC1介导了针对中和的AB反应
两种不同的鼠逆转录病毒(6、2、8)。这是VIC1代表了一种广泛抵抗的机制
逆转录病毒。使用位置克隆和计算方法,我们将H2-OB(OB)确定为基因
编码VIC1(1)。 OB编码由OA编码的Alpha亚基一起编码的Beta亚基
进化上配置了非古典主要组织相容性复合物II类样分子H2-O(HLA--
在人类中做),一种抗原表现的负调节剂。 H2-O/HLA-DO的精确函数仍然
辩论,但它似乎与它通过抑制另一种修改MHC-II肽库的能力有关
MHC-II样分子,H-2M(人类中的HLA-DM)(9)。
通过将OB的I/LNJ等位基因移至
几种具有病毒的背景,例如C3H/HEN,B6和BALB/CJ,并通过产生敲除
B6小鼠基因的等位基因。所有这些动物都会产生逆转录病毒中和ABS。但是,只有效果
如果这些动物被感染为成年人,则具有很高的渗透率。相反,I/LNJ小鼠产生了逆转录病毒 -
中和ABS不论其感染年龄如何,即使它们被感染为新生儿。发现
促使我们寻找I/LNJ新生儿抗性的遗传基础。特征成功链接了
至单个显性染色体15的4.1 MB区域,病毒感染控制器2(VIC2)。 VIC2函数是
仅在没有功能性OB的情况下才明显。赋予了非功能性OB和VIC2I的继承
从所有易感性菌株中产生抗病毒ABS的抗病毒ABS的能力。
许多病毒,包括逆转录病毒,感染了成年人,但也从母亲传给了新生儿
出生和母乳喂养期间。通常认为,新生儿的免疫系统是
欠发达,增加了感染的风险和对许多疫苗的反应。但是,我/lnj
小鼠会产生一种与病毒中和免疫响应,与暴露于年龄的年龄无关
病原体。这是从根本上重要的是要阐明VIC2功能的机制以便
了解新生儿免疫系统的未知特征,并获得刺激的能力
新生儿的生产性病原体特异性免疫。 VIC2的识别和途径的描述
它的控制是该提议的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tatyana V Golovkina其他文献
Tatyana V Golovkina的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tatyana V Golovkina', 18)}}的其他基金
Identification of the gene controlling murine retrovirus in YBR mice
YBR小鼠体内控制鼠逆转录病毒的基因的鉴定
- 批准号:
10724724 - 财政年份:2023
- 资助金额:
$ 46.32万 - 项目类别:
A neonatal mouse model to study retrovirus-specific humoral responses
研究逆转录病毒特异性体液反应的新生小鼠模型
- 批准号:
9789817 - 财政年份:2018
- 资助金额:
$ 46.32万 - 项目类别:
A neonatal mouse model to study retrovirus-specific humoral responses
研究逆转录病毒特异性体液反应的新生小鼠模型
- 批准号:
10459482 - 财政年份:2018
- 资助金额:
$ 46.32万 - 项目类别:
A neonatal mouse model to study retrovirus-specific humoral responses
研究逆转录病毒特异性体液反应的新生小鼠模型
- 批准号:
9988632 - 财政年份:2018
- 资助金额:
$ 46.32万 - 项目类别:
Genetic Basis for Sensitivity of Neonates to Retroviruses
新生儿对逆转录病毒敏感性的遗传基础
- 批准号:
9195081 - 财政年份:2015
- 资助金额:
$ 46.32万 - 项目类别:
相似国自然基金
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
恒星模型中氧元素丰度的变化对大样本F、G、K矮星年龄测定的影响
- 批准号:12303035
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于年龄和空间的非随机混合对性传播感染影响的建模与研究
- 批准号:12301629
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
中国东部地区大气颗粒物的年龄分布特征及其影响因素的模拟研究
- 批准号:42305193
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
- 批准号:
10748606 - 财政年份:2024
- 资助金额:
$ 46.32万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 46.32万 - 项目类别:
Understanding the Mechanisms and Consequences of Basement Membrane Aging in Vivo
了解体内基底膜老化的机制和后果
- 批准号:
10465010 - 财政年份:2023
- 资助金额:
$ 46.32万 - 项目类别:
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
- 批准号:
10551184 - 财政年份:2023
- 资助金额:
$ 46.32万 - 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
- 批准号:
10557547 - 财政年份:2023
- 资助金额:
$ 46.32万 - 项目类别: